Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

This study has been completed.
SignalRX Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Semafore Pharmaceuticals Identifier:
First received: May 20, 2009
Last updated: June 11, 2013
Last verified: June 2013
The purpose of this study is to evaluate the safety and tolerability of SF1126 in patients with advanced or metastatic tumors by assessing the dose limiting toxicities (DLTs) and defining the maximum tolerated dose given twice per week for 4 weeks and ultimately define a recommended phase II dose.

Condition Intervention Phase
Advanced or Metastatic Solid Tumors
Solid Cancers
Drug: SF1126
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors

Resource links provided by NLM:

Further study details as provided by Semafore Pharmaceuticals:

Primary Outcome Measures:
  • To assess the dose limiting toxicities (DLTs) of SF1126 and the maximum tolerated dose given twice per week for 4 weeks and ultimately define a recommended phase II dose. [ Time Frame: Assessed at each visit and end of cycle 1 ]

Secondary Outcome Measures:
  • To assess any preliminary evidence of anti-tumor activity observed with SF1126 [ Time Frame: Through study completion or early study discontinuation ]
  • To characterize the pharmacokinetics following the IV doses on Days 1 and 28 [ Time Frame: Cycle 1 Days 1 and 28 ]

Enrollment: 44
Study Start Date: April 2007
Study Completion Date: April 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SF1126
Twice weekly IV infusion
Drug: SF1126
Dose Escalating with 3+ patients in each cohort

Detailed Description:
SF1126 is a conjugate containing a vascular targeted pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to specific integrins such as αγβ3 that are expressed on the surface of new tumor vasculature and within the tumor compartment. In preclinical xenograft models SF1126 has demonstrated broad activity as a single agent; synergy with commonly used chemotherapy agents, targeted agents, and radiation; and has been shown to reverse resistance mediated through the PI3K/PTEN pathway.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

To qualify for enrollment, all of the following criteria must be met:

  • Written informed consent.
  • At least 18 years old.
  • Accrual will be limited to patients with tumor types that in the opinion of the investigator is known to have PTEN loss or PI3 Kinase mutations potentially important in the biology of their cancer.
  • Only patients with histologically confirmation of advanced solid malignant tumor which is refractory to standard therapies or which no standard therapy exists.
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • Life expectancy of > or = 12 weeks.
  • Female subjects are eligible to enter and participate in the study if: they are non-childbearing potential, had a hysterectomy, had a bilateral oophorectomy (ovariectomy), had a bilateral tubal ligation, post-menopausal or childbearing potential with a negative serum pregnancy test at screening and agrees to protection by IUD, vasectomized partner, complete abstinence, double barrier contraception.
  • male patients with childbearing potential must agree to use adequate contraception while on study.
  • patients on active therapy with well-controlled diabetes as defined by fasting glucose < 160mg/dL.

Exclusion Criteria:

  • Brain metastases or spinal cord compression, unless treatment was completed at least 4 weeks before entry, and stable without steroid treatment for at least 4 weeks.
  • Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count <1.5 x 10^9/L or platelet count < 100 x 10^9/L (can not be post-transfusion) or hemoglobin <9 g/dL (can be post-transfusion).
  • Serum bilirubin > or = 1.2 times the upper limit of normal.
  • An ALT or AST level > or = 2.5 times the upper limit of normal. If documented liver metastases are present, the ALT or AST levels must still be less than 2.5 times the upper limit of normal.
  • Serum creatinine > 1.5 times the upper limit of normal or a creatinine clearance of < or = 50mL/min calculated by the Cockcroft-Gault equation.
  • Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, cardiac [including life threatening arrhythmias], hepatic, or renal disease.
  • Unresolved toxicity ≥CTC Grade 2 from previous anti-cancer therapy except alopecia (if applicable) unless agreed that the patient can be entered after discussion with the Medical Monitor.
  • QTc prolongation defined as a QTc >450 ms for males or >470ms for females (Fridericia) for 3 consecutive ECGs; OR prior history of cardiovascular disease including heart failure that meets New York Hearth Association (NYHA) class III and IV definitions, OR history of myocardial infarction/active ischemic heart disease within one year of study entry; OR uncontrolled dysrhythmias; OR poorly controlled angina.
  • Participation in a trial of an investigational agent within the prior 30 days.
  • Pregnant or breast-feeding females.
  • High volume peritoneal or pleural effusions requiring a tap more frequently than every 14 days.
  • History of other malignancies except curatively excised carcinoma in situ of the cervix, non-melanomatous skin carcinoma or superficial bladder cancer or other solid tumors curatively treated with no evidence of disease for > or = 5 years. Other cases will be reviewed and possibly allowed if discussed with and approved by Medical Monitor.
  • Patients receiving therapeutic doses of Warfarin.
  • Any concurrent condition which in the investigator's opinion makes it undesirable for the subject to participate in this trial or which would jeopardize compliance with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00907205

United States, Arizona
Scottsdale Clinical Research Institute
Scottsdale, Arizona, United States, 85258
Arizona Cancer Center
Tucson, Arizona, United States, 85719
United States, Georgia
Emory Winship Cancer Institute
Atlanta, Georgia, United States, 30322
United States, Indiana
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Semafore Pharmaceuticals
SignalRX Pharmaceuticals, Inc.
Study Chair: Donald L Durden, MD, PhD SignalRX Pharmaceuticals, Inc.
  More Information

Additional Information:
Responsible Party: Semafore Pharmaceuticals Identifier: NCT00907205     History of Changes
Other Study ID Numbers: SF1126-001-06
Study First Received: May 20, 2009
Last Updated: June 11, 2013

Keywords provided by Semafore Pharmaceuticals:
Advanced Solid Tumors
Metastatic Solid Tumors
PI3K Inhibitors
PI3 Kinase Inhibitors
mTORC inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
vascular targeted
conjugate processed this record on April 24, 2017